---
title: "Frozen Animal Blood Plasma Market, Global Outlook and Forecast 2025-2032"
datePublished: Thu Jul 24 2025 12:42:16 GMT+0000 (Coordinated Universal Time)
cuid: cmdhdtwvr001l02gw1iavdkjk
slug: frozen-animal-blood-plasma-market-global-outlook-and-forecast-2025-2032

---

# Frozen Animal Blood Plasma Market, Global Outlook and Forecast 2025-2032

<p><strong>MARKET INSIGHTS</strong></p><p>
</p><p>Global frozen animal blood plasma market size was valued at <strong>USD 1370 million in 2024</strong> and is projected to reach <strong>USD 1961 million by 2032</strong>, growing at a <strong>CAGR of 5.3%</strong> during the forecast period.</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/295430/frozen-animal-blood-plasma-market">
            https://www.24chemicalresearch.com/download-sample/295430/frozen-animal-blood-plasma-market</a></b></div><br><p>
</p><p>Frozen animal blood plasma refers to processed blood components derived from healthy livestock (primarily bovine and porcine sources), preserved through cryogenic storage at temperatures below -20°C. This biological material contains essential proteins like albumin and immunoglobulins, along with bioactive compounds, making it valuable across pharmaceutical, nutritional, and cosmetic applications. The frozen preservation method ensures extended shelf life while maintaining functional integrity.</p><p>
</p><p>The market expansion is driven by increasing pharmaceutical applications in plasma-derived therapeutics and vaccine production, which accounted for 42% of total consumption in 2024. However, supply chain volatility in raw material procurement presents a key challenge, with seasonal fluctuations causing 15-20% price variations annually. Recent technological advancements in plasma fractionation and cold chain logistics are addressing these limitations, with companies like <strong>Grifols</strong> and <strong>CSL</strong> investing over USD 120 million collectively in production facility upgrades during 2023-2024.</p><p>
<strong>MARKET DYNAMICS</strong></p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Rising Demand in Pharmaceutical Applications to Accelerate Market Expansion</strong></p><p>
</p><p>The pharmaceutical industry's growing reliance on frozen animal plasma as a critical raw material for vaccine production and biopharmaceuticals is driving significant market growth. Plasma-derived therapeutics account for approximately <strong>40%</strong> of global biopharmaceutical production, with animal-sourced components playing an increasingly vital role. Recent advancements in plasma fractionation technologies have enhanced yield efficiency by <strong>15-20%</strong>, making frozen plasma more economically viable for large-scale drug manufacturing. Major pharmaceutical companies are expanding their plasma sourcing networks, particularly for bovine and porcine plasma which demonstrate superior compatibility with human therapeutics.</p><p>
</p><p style="text-align:center"><strong>Expansion of Animal Feed Supplement Industry to Fuel Consumption</strong></p><p>
</p><p>The global animal nutrition market's shift toward plasma-based protein supplements is creating sustained demand. Spray-dried plasma products derived from frozen stocks show <strong>12-18% improvements</strong> in livestock growth rates compared to conventional feed additives. With the compound feed market projected to exceed <strong>$600 billion</strong> by 2028, manufacturers are increasingly incorporating plasma proteins in premixes for swine, poultry and aquaculture applications. This trend is particularly strong in Asia-Pacific regions where intensive farming practices require high-performance feed solutions.</p><p>
</p><p style="text-align:center"><strong>Technological Advancements in Plasma Processing to Enhance Market Potential</strong></p><p>
</p><p>Innovations in cryopreservation and pathogen inactivation technologies are eliminating traditional barriers to market growth. Next-generation freezing techniques now maintain <strong>95-98% bioactivity</strong> of plasma components compared to <strong>80-85%</strong> with conventional methods. The development of modular plasma processing units has reduced operational costs by <strong>30%</strong>, enabling mid-sized producers to compete effectively. These technological improvements are creating new application possibilities in cell culture media and diagnostic reagent production.</p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>Stringent Regulatory Frameworks to Constrain Market Development</strong></p><p>
</p><p>Increasing regulatory scrutiny on animal-derived products presents significant challenges for market participants. Compliance with Good Manufacturing Practice (GMP) standards for plasma collection adds <strong>25-35%</strong> to production costs, while traceability requirements necessitate expensive documentation systems. The European Union's revised veterinary medicinal products regulation has delayed <strong>15%</strong> of planned plasma product launches in recent years. Such regulatory hurdles disproportionately affect smaller producers lacking the resources for comprehensive compliance programs.</p><p>
</p><p style="text-align:center"><strong>Supply Chain Vulnerabilities to Limit Market Stability</strong></p><p>
</p><p>The industry faces persistent challenges in maintaining consistent plasma supplies due to animal health regulations and seasonal variations. Disease outbreaks can immediately restrict <strong>40-60%</strong> of available plasma from affected regions, while transportation disruptions increase thawing risks. The African swine fever outbreak in 2022 caused <strong>18%</strong> global shortages in porcine plasma supplies, highlighting the market's exposure to biological risks. These supply uncertainties force manufacturers to maintain costly inventory buffers, reducing profit margins.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>Ethical Concerns and Alternative Technologies to Challenge Traditional Demand</strong></p><p>
</p><p>Growing ethical debates surrounding animal-derived products are prompting some manufacturers to explore plant-based and synthetic alternatives. Cell-cultured plasma proteins already capture <strong>8-12%</strong> of the research reagents market, with technology improvements potentially expanding into therapeutic applications. While currently more expensive than animal plasma, these alternatives benefit from easier regulatory pathways and consistent quality control.</p><p>
</p><p style="text-align:center"><strong>Limited Cold Chain Infrastructure to Impede Market Penetration</strong></p><p>
</p><p>Developing markets face substantial hurdles in establishing reliable frozen plasma distribution networks. Temperature-controlled logistics account for <strong>35-45%</strong> of final product costs in regions lacking specialized infrastructure. Many emerging economies report <strong>15-25%</strong> product loss during transportation due to inadequate freezing capabilities. These logistical barriers significantly slow market expansion into high-growth potential regions.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Emerging Applications in Cell Therapy to Create New Growth Avenues</strong></p><p>
</p><p>The booming cell therapy sector presents lucrative opportunities for specialized plasma products. Serum-free culture media incorporating animal plasma components demonstrate <strong>40% faster</strong> cell proliferation rates than synthetic alternatives. With the cell therapy market projected to exceed <strong>$25 billion</strong> by 2030, plasma producers are developing ultra-purified fractions specifically for regenerative medicine applications. This represents a high-value niche with substantial margin potential.</p><p>
</p><p style="text-align:center"><strong>Strategic Partnerships to Enhance Market Positioning</strong></p><p>
</p><p>Vertical integration across the plasma value chain is emerging as a key competitive strategy. Major players are forming alliances with slaughterhouses to secure <strong>10-15 year</strong> plasma supply agreements, while downstream partnerships with biotech firms ensure stable demand. Such coordinated approaches reduce market volatility and enable more accurate production planning. Recent joint ventures have demonstrated <strong>20-30%</strong> improvements in supply chain efficiency compared to traditional procurement models.</p><p>
<strong>MARKET TRENDS</strong></p><p>
<strong>Expansion in Biomedical Applications Driving Market Growth</strong></p><p>
</p><p>The frozen animal blood plasma market is experiencing significant growth, primarily fueled by its expanding applications in the biomedical sector. <strong>Plasma-derived proteins such as albumin and fibrinogen are increasingly used in wound healing, surgical adhesives, and regenerative medicine.</strong> The global market, valued at approximately <strong>1370 million in 2024</strong>, is projected to reach <strong>1961 million by 2032</strong>, growing at a CAGR of <strong>5.3%</strong>. This growth is attributed to the rising demand for biological therapeutics and advanced medical treatments. Pharmaceutical companies are investing heavily in research to develop plasma-based biologics, particularly for treating immunological disorders and rare diseases. The stability and long shelf-life of frozen plasma make it an indispensable resource for biopharmaceutical manufacturing.</p><p>
<strong>Other Trends</strong></p><p>
</p><p style="text-align:center"><strong>Growing Demand in Animal Feed Supplementation</strong></p><p>
</p><p>Frozen animal plasma is increasingly being used as a high-protein feed supplement for livestock and aquaculture. The feed industry values its rich amino acid profile and bioactive components, which enhance growth performance and immune function in animals. With the global livestock population expanding and aquaculture production rising, the demand for plasma-based feed additives is expected to grow substantially. Additionally, regulatory approvals for plasma-derived ingredients in animal nutrition further support market expansion. Innovations in spray-drying and microencapsulation technologies are improving product stability, ensuring wider adoption in feed formulations.</p><p>
<strong>Sustainability and Supply Chain Optimization</strong></p><p>
</p><p>The frozen animal blood plasma market faces challenges related to raw material sourcing and supply chain efficiency. <strong>Fluctuations in livestock populations due to disease outbreaks and breeding cycles</strong> can disrupt plasma availability. However, advancements in cold-chain logistics and cryopreservation techniques are mitigating these risks. Companies are adopting blockchain technology to enhance traceability from farm to processing facilities, ensuring compliance with stringent quality standards. Furthermore, sustainability initiatives are driving the development of eco-friendly processing methods to minimize waste and energy consumption during plasma extraction and freezing.</p><p>
<strong>COMPETITIVE LANDSCAPE</strong></p><p>
<strong>Key Market Participants</strong></p><p>
</p><p style="text-align:center"><strong>Global Players Dominate While Regional Suppliers Gain Traction Through Specialization</strong></p><p>
</p><p>The frozen animal blood plasma market features a mix of multinational biotechnology firms and specialized regional suppliers. <strong>CSL Limited</strong> leads the market, holding approximately 18% of the global revenue share in 2024, owing to its vertically integrated operations spanning plasma collection networks across multiple continents. The company's leadership stems from its proprietary pathogen-reduction technologies and strategic alliances with livestock producers.</p><p>
</p><p><strong>Grifols S.A.</strong> and <strong>Biovet</strong> represent other major participants, collectively controlling nearly 25% of market share. Their dominance comes from extensive product portfolios addressing both medical and industrial applications, coupled with rigorous quality certifications that meet international standards for biologic products.</p><p>
</p><p>Emerging Asia-Pacific manufacturers like <strong>Tiantan Biological</strong> and <strong>Hualan Biological</strong> are rapidly expanding through government-backed initiatives in China's biopharmaceutical sector. These players leverage domestic livestock resources and cost-competitive production methods to serve regional markets, though they face challenges in meeting EU and FDA compliance standards for export markets.</p><p>
</p><p>Mid-sized innovators such as <strong>Vetoquinol</strong> and <strong>LFB</strong> are carving niche positions by focusing on species-specific plasma products. Vetoquinol's swine plasma derivatives for veterinary applications demonstrate particular strength in European markets, while LFB's bovine serum albumin finds increasing adoption in cell culture media formulations.</p><p>
<strong>List of Prominent Frozen Animal Blood Plasma Suppliers</strong></p><p>
</p><p>CSL Limited (Australia)</p><p><strong>Grifols S.A. (Spain)</strong></p><p>Biovet (France)</p><p>Vetoquinol S.A. (France)</p><p><strong>LFB Group (France)</strong></p><p>Miltenyi Biotec (Germany)</p><p>Baxter International Inc. (U.S.)</p><p>Thermo Fisher Scientific Inc. (U.S.)</p><p>Tiantan Biological (China)</p><p>Hualan Biological Engineering (China)</p><p>
<strong>Segment Analysis:</strong></p><p>
<strong>By Type</strong></p><p>
</p><p><strong>Frozen Bovine Plasma Leads the Market Due to High Protein Content and Wide Applications</strong></p><p>
</p><p>The market is segmented based on type into:</p><p>
</p><p>Frozen Bovine Plasma</p><p>
</p><p>Frozen Pig Plasma</p><p>Others</p><p>
</p><p><strong>By Application</strong></p><p>
</p><p><strong>Pharmaceutical Industry Dominates Due to Demand for Biopharmaceutical Ingredients</strong></p><p>
</p><p>The market is segmented based on application into:</p><p>
</p><p>Pharmaceutical Industry</p><p>Food Industry</p><p>Feed Industry</p><p>Cosmetics Industry</p><p>Others</p><p>
<strong>By Source Animal</strong></p><p>
</p><p><strong>Healthy Sourced Animals Preferred for Product Safety and Regulatory Compliance</strong></p><p>
</p><p>The market is segmented based on source animal health into:</p><p>
</p><p>Regular Health Animals</p><p>Disease-free Certified Animals</p><p>
<strong>By Processing Method</strong></p><p>
</p><p><strong>Centrifugation Remains Primary Processing Technique for Plasma Separation</strong></p><p>
</p><p>The market is segmented based on processing method into:</p><p>
</p><p>Centrifugation</p><p>Filtration</p><p>Combination Methods</p><p>Others</p><p>
<strong>Regional Analysis: Frozen Animal Blood Plasma Market</strong></p><p>
</p><p><strong>North America</strong></p><p>
</p><p>The North American frozen animal blood plasma market benefits from a well-regulated healthcare system and strong demand for biopharmaceutical applications, driving steady growth. <strong>The U.S.</strong> leads the region, accounting for approximately <strong>65%</strong> of regional market share, supported by strict FDA regulations on raw material sourcing and processing standards. The feed industry's shift toward high-protein supplements, particularly in livestock farming, further fuels demand. However, supply chain constraints due to stringent animal welfare regulations pose challenges. Market leaders like <strong>CSL, Abbott Laboratories, and Baxter International</strong> dominate with investments in lyophilization technology to enhance product stability and shelf life. Canada presents niche opportunities, with increasing adoption in veterinary medicine and research applications.</p><p>
</p><p><strong>Europe</strong></p><p>
</p><p>Europe's market is characterized by stringent EU regulations, such as <strong>Directive 2001/82/EC</strong>, ensuring product safety in pharmaceuticals and cosmetics. Germany and France account for the largest shares due to advanced biotech infrastructure and strong R&amp;D pipelines, while the Nordic countries prioritize sustainable plasma sourcing. The region sees growing demand for <strong>frozen bovine plasma</strong> in cell culture media for vaccine development. However, ethical concerns around animal-derived products are pushing manufacturers to explore synthetic alternatives, potentially slowing market expansion. Major players like <strong>LFB and Grifols</strong> focus on traceability and organic certification to maintain competitive advantage.</p><p>
</p><p><strong>Asia-Pacific</strong></p><p>
</p><p>This region dominates global volume consumption, with <strong>China (&gt;50% share)</strong> driving growth through large-scale livestock production and government-backed biotech initiatives. The feed industry relies heavily on frozen pig plasma as a cost-effective protein source, though recent swine fever outbreaks have disrupted supply chains. India shows potential with rising pharmaceutical outsourcing and increasing investments in cold storage infrastructure. Japan and South Korea lead in high-value applications, such as regenerative medicine. While price sensitivity limits premium product adoption, domestic players like <strong>Tiantan Biological and Hualan Biological</strong> are expanding capacity to meet regional demand.</p><p>
</p><p><strong>South America</strong></p><p>
</p><p>Brazil's thriving meatpacking industry provides abundant raw materials, positioning it as the regional leader in frozen plasma production. The Argentinian market is growing steadily due to exports to European pharmaceutical companies, albeit hampered by economic instability. Chile and Colombia show emerging demand for plasma-based feed additives in aquaculture. However, inconsistent regulatory frameworks and limited cold chain logistics hinder market maturity. Local manufacturers prioritize partnerships with global firms like <strong>Vetoquinol</strong> to access advanced processing technologies and expand market reach.</p><p>
</p><p><strong>Middle East &amp; Africa</strong></p><p>
</p><p>The market remains nascent but shows promising growth in <strong>GCC countries</strong>, where imported plasma is used in premium pet food and cosmetic formulations. South Africa leads in veterinary applications, though high refrigeration costs limit broader adoption. The region's reliance on imports creates price volatility, but local production initiatives in the UAE and Saudi Arabia aim to reduce dependency. Religious and cultural sensitivities around animal blood products present unique challenges, requiring tailored marketing strategies. Long-term opportunities exist in vaccine production as regional healthcare infrastructure develops.</p><p>
<strong>Report Scope</strong></p><p>
</p><p>This report presents a comprehensive analysis of the global and regional markets for Frozen Animal Blood Plasma, covering the period from 2024 to 2032. It includes detailed insights into the current market status and outlook across various regions and countries, with specific focus on:</p><p>
</p><p><strong>Sales, sales volume, and revenue forecasts</strong></p><p><strong>Detailed segmentation by type and application</strong></p><p>
</p><p>In addition, the report offers in-depth profiles of key industry players, including:</p><p>
</p><p>Company profiles</p><p>Product specifications</p><p>Production capacity and sales</p><p>Revenue, pricing, gross margins</p><p>Sales performance</p><p>
</p><p>It further examines the competitive landscape, highlighting the major vendors and identifying the critical factors expected to challenge market growth.</p><p>
</p><p>As part of this research, we surveyed Frozen Animal Blood Plasma companies and industry experts. The survey covered various aspects, including:</p><p>
</p><p>Revenue and demand trends</p><p>Product types and recent developments</p><p>Strategic plans and market drivers</p><p>Industry challenges, obstacles, and potential risks</p><p>
<strong>FREQUENTLY ASKED QUESTIONS:</strong></p><p>
<strong>What is the current market size of Global Frozen Animal Blood Plasma Market?</strong></p><p>
</p><p>-&gt; Global Frozen Animal Blood Plasma market was valued at USD 1370 million in 2024 and is projected to reach USD 1961 million by 2032, growing at a CAGR of 5.3% during the forecast period.</p><p>
<strong>Which key companies operate in Global Frozen Animal Blood Plasma Market?</strong></p><p>
</p><p>-&gt; Key players include Biovet, CSL, Vetoquinol, LFB, Miltenyi Biotec, Grifols, Tiantan Biological, Hualan Biological, and other prominent manufacturers.</p><p>
<strong>What are the key growth drivers?</strong></p><p>
</p><p>-&gt; Key growth drivers include rising demand in biopharmaceutical applications, increasing preference for natural ingredients in food/cosmetics, and technological advancements in plasma processing.</p><p>
<strong>Which region dominates the market?</strong></p><p>
</p><p>-&gt; Asia-Pacific shows the fastest growth rate due to expanding pharmaceutical sector, while North America currently holds the largest market share.</p><p>
<strong>What are the emerging trends?</strong></p><p>
</p><p>-&gt; Emerging trends include development of pathogen-reduced plasma products, adoption of automated processing technologies, and increasing regulatory focus on plasma safety standards.</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/295430/frozen-animal-blood-plasma-market">
            https://www.24chemicalresearch.com/reports/295430/frozen-animal-blood-plasma-market</a></b></div><br>
            <b>Table of Content:</b><p>1 Introduction to Research & Analysis Reports<br />
 1.1 Frozen Animal Blood Plasma Market Definition<br />
 1.2 Market Segments<br />
 1.2.1 Segment by Type<br />
 1.2.2 Segment by Application<br />
 1.3 Global Frozen Animal Blood Plasma Market Overview<br />
 1.4 Features & Benefits of This Report<br />
 1.5 Methodology & Sources of Information<br />
 1.5.1 Research Methodology<br />
 1.5.2 Research Process<br />
 1.5.3 Base Year<br />
 1.5.4 Report Assumptions & Caveats<br />
2 Global Frozen Animal Blood Plasma Overall Market Size<br />
 2.1 Global Frozen Animal Blood Plasma Market Size: 2024 VS 2032<br />
 2.2 Global Frozen Animal Blood Plasma Market Size, Prospects & Forecasts: 2020-2032<br />
 2.3 Key Market Trends, Opportunity, Drivers and Restraints<br />
 2.3.1 Market Opportunities & Trends<br />
 2.3.2 Market Drivers<br />
 2.3.3 Market Restraints<br />
3 Company Landscape<br />
 3.1 Top Frozen Animal Blood Plasma Players in Global Market<br />
 3.2 Top Global Frozen Animal Blood Plasma Companies Ranked by Revenue<br />
 3.3 Global Frozen Animal Blood Plasma Revenue by Companies<br />
 3.4 Top 3 and Top 5 Frozen Animal Blood Plasma Companies in Global Market, by Revenue in 2024<br />
 3.5 Global Companies Frozen Animal Blood Plasma Product Type<br />
 3.6 Tier 1, Tier 2, and Tier 3 Frozen Animal Blood Plasma Players in Global Market<br />
 3.6.1 List of Global Tier 1 Frozen Animal Blood Plasma Companies<br />
 3.6.2 List of Global Tier 2 and Tier 3 Frozen Animal Blood Plasma Companies<br />
4 Sights by Product<br />
 4.1 Overview<br />
 4.1.1 Segmentation by Type - Global Frozen Animal Blood Plasma Market Size Markets, 2024 & 2032<br />
 4.1.2 Froz</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/295430/frozen-animal-blood-plasma-market">
            https://www.24chemicalresearch.com/reports/295430/frozen-animal-blood-plasma-market</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>